OutcomesOutcome
PANSS general psychopathology subscale score
1 finding from 1 compound ↓reported in points (16-112)
What moved it
How to read these marks1 finding · 1 compound · by evidence strength. No dose is advised.
PANSS general psychopathology subscale score
Findings drawn, by strength
1finding · 1 compound
- Very limited1
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
Not pooled · no summary effect · point at a mark · Tab, then the arrow keys
Reported to move it1 finding
- L-theanineMoved: lowersEvidence: Very limitedPaper: PMID 212085862011
- Who
- Chronic schizophrenia or schizoaffective disorder (DSM-IV); antipsychotic treatment continued in both arms as background; 8-week 2-center trial; PANSS 3-dimensional model
- Dose studied
- L-theanine 400 mg/d added to ongoing antipsychotic
Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).”
Quoted verbatim from L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.RCT · 8 weeksPermalink
No row matches these filters.
How it is measured
Sum of the sixteen general psychopathology items (G1 to G16, among them somatic concern, anxiety, guilt, tension, depression, disorientation, poor attention, lack of judgement and insight, and active social avoidance) of the PANSS (Kay, Fiszbein and Opler 1987), each rated 1 to 7, summed to 16 to 112; higher is worse.
Measured, with no finding
1 measurement
Show what was measuredHide what was measured
PANSS general psychopathology subscale score
d=0.84
Not recorded as a finding: The only sentence names two subscales together and names no comparator, so it does not support one claim on its own (one outcome per quote).
Statistically significant improvement was also evident for the PANSS negative (d=0.68) and general psychopathology (d=0.84) subscales (Table 2).
PMID 28289280 · one of two readings recorded this
Papers about it
As an endpoint2
Show the papersHide the papers
Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
Molecular psychiatry2018PMID 28289280Via: named in the paper, as read
L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.
The Journal of clinical psychiatry2011PMID 21208586Via: named in the paper, as read
Newest
Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
Molecular psychiatry2018PMID 28289280As an endpoint
L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.
The Journal of clinical psychiatry2011PMID 21208586As an endpoint